Innovation for Life

Circulate is developing science-based therapeutics that expand your quality of life and healthy lifespan.

DRIVEN BY SCIENTIFIC EVIDENCE

We are Pioneering Technologies to Reverse Aging and Improve Health Outcomes.

Rigorous scientific research is at the core of what we do. We are committed to innovating how people live healthier and longer lives by centering our approach on extensive research and clinical trials. Our patented flagship product, Therapeutic Plasma Exchange by Circulate, is improving lives today.

Learn More

Our Team

Spanning diverse backgrounds and disciplines, the Circulate team is passionate about enabling successful outcomes for our partners and patients.

Dr. Brad Younggren

Co-founder, CEO

Dr. Dobri Kiprov

Co-founder, CMO

Dr. Eric Verdin

Co-Founder, Advisor

Robbie Schwietzer

Chief Operating Officer

Chrissy Anderson

Vice President, Nursing

Stella Bayraktar

Chief of Staff

Sara Otepka

Chief Marketing Officer

Keeli Rose

Sr Clinic Success Manager

Christina Ristovski

Sr Clinic Success Manager

David Furman, PhD

Scientific Advisory Board

Alex Aravanis, MD, PhD

Scientific Advisory Board

Our Journey So Far

Early 2000s

RESEARCH AND INNOVATION

The journey began with Dr. Dobri Kiprov's scientific leadership and clinical trial research, driven by a vision to help people live longer, healthier lives. Dr. Kiprov has published extensively on therapeutic plasma exchange (TPE) and was the first and only to publish on TPE's effects on aging. Dr. Kiprov has set himself apart in the longevity field by working diligently to find treatments built from rigorous scientific methods and extensive clinical research.

2020s

PRIORITIZING SCIENCE AND SAFETY

Building a two-decade foundation of research and innovation, Dr. Kiprov and team focused on studying and testing safe and effective treatments for patients. The apheresis device that is used for Therapeutic Plasma Exchange (TPE) received FDA-clearance, and the FDA references TPE clinical practice guidelines published by the American Society for Apheresis in 2023. These guidelines classify common diseases, including neurological disorders, hematological conditions and autoimmune diseases, based on the strength of evidence and the effectiveness of TPE.

THE CIRCULATE TRIAL

Reducing Biological Age
with Therapeutic Plasma Exchange

Circulate's research focused on finding a therapy that reduces biological age, which is a measure of how much your body has aged on a molecular level, rather than simply the number of years you have lived. Conducted over a two-year period and published in July 2024, the Circulate Trial studied therapeutic plasma exchange (TPE), a procedure that separates the plasma and replaces it with albumin and intravenous immunoglobulin (IVIG). The study looks at how the TPE procedure may reduce biological age.